Financial Times Examines Legal Disputes in India Over Pharmaceutical Patent LawsView Full Article
The Financial Times reports on a legal dispute between the Indian government and the German pharmaceutical group Bayer, writing, "Bayer is appealing against the Indian patent controller's decision in March to override the company's monopoly on its cancer drug Nexavar, and to allow an Indian company to produce and sell the life-extending drug for just $173 a month -- one-sixth of the $5,500 a month price charged by Bayer." According to the newspaper, "If Bayer loses the appeal, and the court upholds the compulsory license issued to Natco, a generics producer based in the central Indian city of Hyderabad, the precedent could encourage other Indian manufacturers to follow its lead by producing cheap generic versions of high-priced, patented drugs that are out of the reach of all but the wealthiest Indians."
Comment by: michael
Wed., Oct. 3, 2012 at 4:35 am EDT
keep a close eye on this one folks. this could affect you should health care turn for the worse in this country.
the idea of patenting life saving medicines still sickens me to this day.
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy